Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
Ceejay L BoyceIngrid A BeckSheila M StyrchakSamantha R HardyJackson J WallnerRoss S MilneR Leavitt MorrisonDavid E ShapiroEsaú C JoãoMark H MirochnickLisa M FrenkelPublished in: PloS one (2022)
We observed a moderate frequency of PDR that did not significantly contribute to virologic non-suppression at term. Rather, higher pretreatment plasma HIV RNA, randomization to efavirenz-based ART, and shorter duration of ART were associated with non-suppression. These findings support early prenatal care engagement of pregnant women and initiation of integrase inhibitor-based ART due to its association with more rapid suppression of plasma RNA levels. Furthermore, because minority variants appeared infrequent in ART-naïve pregnant women and inconsequential to ART-suppression, testing for minority variants may be unwarranted.
Keyphrases
- antiretroviral therapy
- hiv infected
- pregnant women
- drug resistant
- human immunodeficiency virus
- hiv positive
- hiv infected patients
- hiv aids
- copy number
- multidrug resistant
- healthcare
- acinetobacter baumannii
- pregnancy outcomes
- preterm infants
- gene expression
- social media
- genome wide
- pseudomonas aeruginosa
- clinical evaluation
- loop mediated isothermal amplification